Illuminating the druggable genome through patent bioactivity data is a dataset published in PeerJ (2023). On theSindex it has a DataRank of 1.5, placing it in the top 13.4% of the data-sharing corpus. It has been cited 12 times, with 9 citing works in its 1-hop citation network. Its calibrated FAIR score is 42/100.
Ranks in the top 13% for downstream scientific impact
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
Full FAIR picture · advisory
The headline score is computed from the scored criteria — the fact-shaped checks (a repository, an accession, a licence) that two independent models agree on. The advisory criteria below are real FAIR guidance but rest on judgment calls that models read differently, so they inform without moving the number.
The paper does not provide a persistent identifier (DOI, Handle, ARK, or repository accession) for the curated bioactivity data deposited in ChEMBL. [majority verdict 'no' (4/5 passes agreed)]
RDA-F1-01D — FAIR Data Maturity Model: 'Data is identified by a persistent identifier' (priorit · RDA-F1-02D — FAIR Data Maturity Model: 'Data is identified by a globally unique identifier' · FsF-F1-02D — F-UJI/FAIRsFAIR: 'Data is assigned a persistent identifier'
“The small molecules found in these patents, together with their measured activity against the targets, are now accessible via the ChEMBL database”
The paper states that the data are accessible via the ChEMBL database, a recognised data repository.
RDA-F4-01M — FAIR Data Maturity Model: metadata is offered so it can be harvested and indexed ( · NIH DMS Policy Element 4 (NOT-OD-21-014) — name the repository where data will be archived · NSTC Desirable Characteristics of Data Repositories (2022) — 'Long-Term Sustainability', 'Reten
No identifier or link for the dataset appears in the reference list or body text; the dataset is not cited as a reference. [majority verdict 'no' (3/5 passes agreed)]
FORCE11 Joint Declaration of Data Citation Principles (2014) — data should be cited as a first- · RDA-F3-01M — metadata clearly and explicitly includes the identifier of the data it describes · FsF-F3-01M — F-UJI: 'Metadata includes the identifier of the data it describes'
Advisory · not in the published score
“The list of patents and targets found in the search, the list of targets for which at least 1 compound with bioactivity data within cut-off values per target family was found, and the number of compounds found per target, are all available in the Supplemental Files.”— not found in the paper; verdict downgraded
The data availability statement points to supplemental files, which corresponds to Colavizza category 2 (data contained within the article and its supplementary materials). [downgraded to 'no' — no verifiable quote from the paper] [majority verdict 'no' (4/5 passes agreed)]
Colavizza, Hrynaszkiewicz, Staden, Whitaker & McGillivray (2020), 'The citation advantage of li · Springer Nature research data policy — Data Availability Statements: standard statement templat · RDA-F3-01M — metadata clearly and explicitly includes the identifier of the data it describes
“bioactivity data from 225 patents were loaded into ChEMBL, corresponding to 657 targets (including single proteins, protein families, protein complexes, organisms, cell lines and protein-protein interactions) and 18,319 compounds.”
The dataset content is described in a single prose sentence; no itemised inventory, table, or section is provided. [majority verdict 'partial' (4/5 passes agreed)]
RDA-F2-01M — 'Rich metadata is provided to allow discovery' (priority Essential) · FsF-F2-01M — F-UJI: 'Metadata includes descriptive core elements to support data findability' · FsF-R1-01MD — F-UJI: 'Metadata specifies the content of the data'
“The list of patents and targets found in the search, the list of targets for which at least 1 compound with bioactivity data within cut-off values per target family was found, and the number of compounds found per target, are all available in the Supplemental Files”
The data are freely available in the Supplemental Files with no stated precondition.
RDA-A1.1-01D — 'Data is accessible through a free access protocol' · FsF-A1-01M — F-UJI: 'Metadata contains access level and access conditions of the data' · NSTC Desirable Characteristics of Data Repositories (2022) — 'Free and Easy Access'
Advisory · not in the published score
“The small molecules found in these patents, together with their measured activity against the targets, are now accessible via the ChEMBL database.”
The paper states that the data are accessible via ChEMBL without using an explicit access-level label like 'open access' or 'freely available', so the access level must be inferred. [majority verdict 'partial' (4/5 passes agreed)]
FsF-A1-01M — F-UJI: 'Metadata contains access level and access conditions of the data' · RDA-A1-01M — metadata contains information to enable the user to get access to the data · COAR Controlled Vocabularies — Access Rights v1.0 (open / embargoed / restricted / metadata-onl
The data are not sensitive human-subject data; no gatekeeper is mentioned.
NIH Genomic Data Sharing Policy (NOT-OD-14-124) — controlled-access via a Data Access Committee · RDA-A1.2-01D — 'Data is accessible through an access protocol that supports authentication and · NIH DMS Policy Element 5 (NOT-OD-21-014) — Access, Distribution, or Reuse Considerations (conse
The paper does not state any retention period or persistence commitment for the data.
NIH DMS Plan Element 4 (NOT-OD-21-014) — Data Preservation, Access, and Associated Timelines · NSTC Desirable Characteristics (2022), Organizational Infrastructure: 'Retention Policy' · RDA-A2-01M — 'Metadata is guaranteed to remain available after data is no longer available'
The paper does not specify the file format of the supplemental data files.
FsF-R1.3-02D — F-UJI: 'Data is available in a file format recommended by the target research co · RDA-R1.3-02D — data is expressed in a machine-understandable community standard · RDA-I1-01D — data uses a knowledge representation expressed in a standardised format
Advisory · not in the published score
No data or metadata community standard is explicitly named for the dataset. [majority verdict 'no' (4/5 passes agreed)]
RDA-R1.3-01M — 'Metadata complies with a community standard' (priority Essential) · RDA-R1.3-01D — 'Data complies with a community standard' · RDA-I2-01M — '(Meta)data use vocabularies that follow FAIR principles'
“Maria Paula Magarinos & Eloy Félix. (2023). chembl/idg_patents_paper: 1.0 (1.0). Zenodo. https://doi.org/10.5281/zenodo.7669601”— not found in the paper; verdict downgraded
The paper provides a DOI for the code repository, which is a qualified reference to an external resource. [downgraded to 'no' — no verifiable quote from the paper] [majority verdict 'no' (3/5 passes agreed)]
RDA-I3-01M — '(meta)data include references to other (meta)data' · RDA-I3-03M — 'metadata includes qualified references to other metadata' · FsF-I3-01M — F-UJI: 'Metadata includes links between the data and its related entities'
No license or terms of use are stated for the data; the CC BY license applies to the article only. [majority verdict 'no' (4/5 passes agreed)]
RDA-R1.1-01M — 'Metadata includes information about the licence under which the data can be reu · RDA-R1.1-02M — 'Metadata refers to a standard reuse licence' · RDA-R1.1-03M — 'Metadata refers to a machine-understandable reuse licence'
The paper does not provide a version token or date for the data snapshot in ChEMBL. [majority verdict 'no' (4/5 passes agreed)]
DataCite Metadata Schema 4.6 — the 'Version' property · RDA-R1.2-01M — provenance information (which version was used is provenance) · NSTC Desirable Characteristics of Data Repositories (2022) — 'Provenance', 'Retention Policy'
“The scripts to process the patents are available at GitHub and Zenodo: https://github.com/chembl/idg_patents_paper . Maria Paula Magarinos & Eloy Félix. (2023). chembl/idg_patents_paper: 1.0 (1.0). Zenodo. https://doi.org/10.5281/zenodo.7669601”— not found in the paper; verdict downgraded
The paper provides a machine-resolvable locator (GitHub URL and Zenodo DOI) for the code. [downgraded to 'partial' — no verifiable quote from the paper]
NIH DMS Policy Element 2 (NOT-OD-21-014) — 'Related Tools, Software and/or Code' · FAIR4RS Principles v1.0 (Chue Hong et al., 2022; RDA/FORCE11/ReSA) — FAIR Principles for Resear · FORCE11 Software Citation Principles (Smith, Katz & Niemeyer, 2016, PeerJ CS 2:e86)
“U54 CA189205”
The paper includes an alphanumeric grant number from a named funder.
DataCite Metadata Schema 4.6 — 'FundingReference' property (funderName, funderIdentifier, award · Crossref Funder Registry — canonical funder identifiers for funding metadata · RDA-F2-01M — rich metadata provided to allow discovery (funding is part of the descriptive reco
Advisory · not in the published score
“For patents with confirmed bioactivity data, details of compounds synthesised, biological assays performed, and bioactivity measurements were manually extracted according to the standard ChEMBL curation procedure described previously ( Gaulton et al., 2015 ) and loaded into the ChEMBL database.”
The production method is described generically without naming specific instruments, kits, or software versions. [majority verdict 'partial' (3/5 passes agreed)]
RDA-R1.2-01M — 'Metadata includes provenance information according to community- specific standa · FsF-R1.2-01M — F-UJI: 'Metadata includes provenance information about data creation or generati · W3C PROV-O (W3C Recommendation, 2013) — the entity/activity/agent model of provenance
“The list of patents and targets found in the search, the list of targets for which at least 1 compound with bioactivity data within cut-off values per target family was found, and the number of compounds found per target, are all available in the Supplemental Files.”— not found in the paper; verdict downgraded
The variable and file definitions are provided in the supplemental files, which are part of the article rather than a separate documentation object shipped with the data. [downgraded to 'no' — no verifiable quote from the paper] [majority verdict 'no' (4/5 passes agreed)]
RDA-R1-01M — '(Meta)data are richly described with a plurality of accurate and relevant attribu · FsF-R1-01MD — F-UJI: 'Metadata specifies the content of the data' · NIH DMS Policy Element 3 (NOT-OD-21-014) — Standards (documentation and metadata to accompany t
Calibrated FAIR score — a parallel quality metric, independent of the DataRank citation score. See the full evaluation →
Base Score Contribution
0.385
From this paper's citation signal
Citation Network Contribution
1.2
From 6 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 9 citers.
US National Institutes of Health
Grant: U54 CA189205 and U24 224370
Wellcome Trust
Grant: 104104/A/14/Z and 218244/Z/19/Z
Wellcome Trust
Grant: 104104/A/14/Z
Wellcome Trust
Grant: 218244/Z/19/Z
NCI NIH HHS
Grant: U54 CA189205
Wellcome Trust
Grant: 218244
The ChEMBL database
National Institutes of Health
Grant: 3U54CA189205-02S1
Illuminating the Druggable Genome Knowledge Management Center (IDG KMC)
Wellcome Trust
Grant: 104104
The ChEMBL Database An Open Resource for Drug Discovery
National Institutes of Health
Grant: 5U24CA224370-06
Knowledge Management Center for Illuminating the Druggable Genome
Member States of the European Molecular Biology Laboratory
Novo Nordisk Foundation Center for Protein Research
Illuminating the Druggable Genome Knowledge Management Center (IDG KMC) at the University of New Mexico
European Bioinformatics Institute (EBI) and University of Miami
FWCI
2.07
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals